Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
1.500
+0.020 (+1.35%)
Streaming Delayed Price
Updated: 3:37 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
18,874
Open
1.600
Bid (Size)
1.500 (8)
Ask (Size)
1.800 (3)
Prev. Close
1.480
Today's Range
1.240 - 1.700
52wk Range
0.0500 - 2.500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Performance
YTD
+200.00%
+200.00%
1 Month
+76.49%
+76.49%
3 Month
+354.55%
+354.55%
6 Month
+614.29%
+614.29%
1 Year
+150.33%
+150.33%
More News
Read More
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 07, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study
March 05, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 16, 2024
Via
ACCESSWIRE
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
March 04, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 01, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
February 20, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 16, 2024
Via
ACCESSWIRE
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Via
ACCESSWIRE
Lexaria's Submits Investigational New Drug Application
January 30, 2024
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 24, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
January 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Investigational New Drug Application Filing Update
December 07, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
November 28, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
November 28, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
November 27, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 13, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
October 12, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Granted Two New Patents in Canada
October 12, 2023
Via
ACCESSWIRE
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 29, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
September 21, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.